Scientists test Triple-Drug attack on devastating youth cancer

This early-stage study is testing whether adding three new drugs (irinotecan, temozolomide, and bevacizumab) to the standard high-dose chemotherapy can help control a rare and aggressive cancer called Desmoplastic Small Round Cell Tumor (DSRCT). The main goal is to see if this combination is safe and tolerable for newly diagnosed patients, who are mostly children and young adults under 30. Researchers will also look for early signs that the treatment might shrink tumors or slow the cancer's progression.